ARE Plunges to $235M Loss on Massive Real Estate Impairments

TL;DR

**SELL ARE; massive real estate impairments signal a tough market ahead for this life science REIT.**

AI Summary

Alexandria Real Estate Equities, Inc. (ARE) reported a significant net loss of $234.9 million for the three months ended September 30, 2025, a stark contrast to the net income of $164.7 million in the same period of 2024. This downturn was primarily driven by a substantial impairment of real estate, totaling $323.9 million in Q3 2025, up from $5.7 million in Q3 2024. For the nine months ended September 30, 2025, the company recorded a net loss of $356.1 million, compared to a net income of $374.5 million in the prior year. Total revenues decreased to $751.9 million for the quarter, down from $791.6 million year-over-year, and to $2.27 billion for the nine-month period, a decline from $2.33 billion. Interest expenses also rose, reaching $54.9 million for the quarter, up from $43.6 million, and $161.0 million for the nine months, compared to $130.2 million. Despite these losses, the company maintained a strong asset base of $37.4 billion as of September 30, 2025, and reported $579.5 million in cash and cash equivalents.

Why It Matters

This filing reveals a significant shift in ARE's financial performance, moving from profitability to a substantial net loss, primarily due to real estate impairments. For investors, this signals potential valuation challenges within their property portfolio and could impact future dividend stability, especially given the REIT structure. Employees might face increased scrutiny on project performance, while customers could see a more cautious approach to new developments. In the broader market, this impairment could reflect a softening in the life science real estate sector, a niche ARE pioneered, potentially affecting competitors and the overall commercial real estate outlook. The competitive landscape may intensify as ARE navigates these valuation adjustments.

Risk Assessment

Risk Level: high — The risk level is high due to the significant impairment of real estate, which jumped from $5.7 million in Q3 2024 to $323.9 million in Q3 2025, and from $36.5 million to $485.6 million for the nine months ended September 30, 2025. This substantial increase in impairment charges directly led to a net loss of $234.9 million for the quarter, indicating potential overvaluation of assets or deteriorating market conditions in their core life science real estate niche.

Analyst Insight

Investors should consider reducing exposure to ARE given the substantial real estate impairments and net loss. Monitor future filings closely for any further asset write-downs or signs of stabilization in the life science real estate market. Re-evaluate the company's long-term growth prospects in light of these significant valuation adjustments.

Financial Highlights

debt To Equity

0.77

revenue

$751.9M

operating Margin

N/A

total Assets

$37.38B

total Debt

$13.59B

net Income

-$197.8M

eps

-$1.38

gross Margin

N/A

cash Position

$579.5M

revenue Growth

-4.9%

Revenue Breakdown

Key Numbers

• $234.9M — Net Loss Attributable to Common Stockholders (For the three months ended September 30, 2025, a significant decline from $164.7 million net income in Q3 2024.)
• $323.9M — Real Estate Impairment (For the three months ended September 30, 2025, a substantial increase from $5.7 million in Q3 2024, driving the net loss.)
• $485.6M — Real Estate Impairment (Nine Months) (For the nine months ended September 30, 2025, a significant increase from $36.5 million in the prior year.)
• $751.9M — Total Revenues (For the three months ended September 30, 2025, a decrease from $791.6 million in Q3 2024.)
• $1.38 — Basic Net Loss Per Share (For the three months ended September 30, 2025, compared to $0.96 basic net income per share in Q3 2024.)
• $161.0M — Interest Expense (Nine Months) (For the nine months ended September 30, 2025, an increase from $130.2 million in the prior year.)
• $37.4B — Total Assets (As of September 30, 2025, a slight decrease from $37.5 billion as of December 31, 2024.)
• $579.5M — Cash and Cash Equivalents (As of September 30, 2025, an increase from $552.1 million as of December 31, 2024.)

Key Players & Entities

• ALEXANDRIA REAL ESTATE EQUITIES, INC. (company) — registrant
• ARE (company) — trading symbol
• New York Stock Exchange (regulator) — exchange where ARE is registered
• $234,937 (dollar_amount) — net loss attributable to common stockholders for Q3 2025
• $164,674 (dollar_amount) — net income attributable to common stockholders for Q3 2024
• $323,870 (dollar_amount) — impairment of real estate for Q3 2025
• $5,741 (dollar_amount) — impairment of real estate for Q3 2024
• $751,944 (dollar_amount) — total revenues for Q3 2025
• $791,607 (dollar_amount) — total revenues for Q3 2024
• $54,852 (dollar_amount) — interest expense for Q3 2025
• $43,550 (dollar_amount) — interest expense for Q3 2024

FAQ

Risk Factors

• Significant Real Estate Impairment [high — financial]: The company recorded a substantial real estate impairment of $323.9 million in Q3 2025, a significant increase from $5.7 million in Q3 2024. This directly contributed to the net loss of $197.8 million for the quarter.
• Increased Interest Expenses [medium — financial]: Interest expenses rose to $54.9 million for the three months ended September 30, 2025, up from $43.6 million in the prior year. For the nine-month period, interest expense was $161.0 million, compared to $130.2 million in 2024.
• Declining Revenues [medium — market]: Total revenues decreased to $751.9 million for Q3 2025 from $791.6 million in Q3 2024. For the nine-month period, revenues declined to $2.27 billion from $2.33 billion.
• Net Loss Position [high — financial]: The company reported a net loss of $234.9 million for the three months ended September 30, 2025, a stark contrast to a net income of $164.7 million in the same period of 2024. The nine-month net loss was $356.1 million.
• Deterioration in Equity [medium — financial]: Total stockholders' equity decreased from $22.38 billion as of December 31, 2024, to $21.06 billion as of September 30, 2025, largely due to the net losses incurred.
• Increased Total Liabilities [medium — financial]: Total liabilities increased to $16.26 billion as of September 30, 2025, from $15.13 billion as of December 31, 2024, driven partly by an increase in unsecured senior line of credit and commercial paper.

Industry Context

Alexandria Real Estate Equities, Inc. operates as a pioneer in the life science real estate niche, focusing on developing collaborative 'Megacampus' ecosystems in key innovation clusters. The company is a leading owner, operator, and developer in this specialized sector, which requires significant capital investment and long-term development cycles. The industry is characterized by high demand for specialized facilities driven by biotech and pharmaceutical research and development.

Regulatory Implications

As a publicly traded REIT, ARE is subject to SEC regulations and accounting standards (GAAP). Changes in real estate valuation methods or tax laws could impact its financial reporting and profitability. The company's disclosures in the 10-Q are mandated by these regulatory bodies to ensure transparency for investors.

What Investors Should Do

1. Monitor the drivers behind the significant real estate impairment ($323.9M in Q3 2025) to understand its impact on future valuations and cash flows.
2. Analyze the trend of increasing interest expenses ($54.9M in Q3 2025) and its effect on profitability, especially in light of declining revenues.
3. Evaluate the company's strategy for managing its substantial asset base ($37.4B) and debt levels ($16.26B in total liabilities) in the current challenging financial environment.
4. Assess the sustainability of the dividend payout in light of the current net loss and the company's cash position ($579.5M).

Key Dates

• 2025-09-30: End of Q3 2025 — Reported significant net loss of $234.9M, driven by a $323.9M real estate impairment.
• 2024-09-30: End of Q3 2024 — Reported net income of $164.7M, with minimal real estate impairment of $5.7M.
• 2025-12-31: End of Fiscal Year 2024 — Total assets were $37.53B, and total liabilities were $15.13B.

Glossary

REIT

Real Estate Investment Trust. A company that owns, operates, or finances income-generating real estate. (ARE is identified as an S&P 500 life science REIT, indicating its business model and industry classification.)

Impairment of real estate

A reduction in the carrying value of a real estate asset on the balance sheet when its fair value is less than its book value. (A major driver of the current period's net loss, with a significant increase in Q3 2025.)

RSF

Rentable Square Feet. The total area of a property that can be leased to tenants. (Used to describe the scale of ARE's operating properties and those under construction (39.1 million RSF of operating properties).)

Noncontrolling interests

The portion of equity in a subsidiary that is not attributable to the parent company. (Represents a significant portion of the company's total equity and impacts net income attributable to common stockholders.)

Deferred rent

Rent revenue that has been earned but not yet recognized, typically due to straight-lining rental income over the lease term. (A significant asset on the balance sheet ($1.26B as of Sep 30, 2025), reflecting future rental income.)

Year-Over-Year Comparison

Compared to the prior year's third quarter, Alexandria Real Estate Equities, Inc. has experienced a significant downturn. Total revenues decreased by 4.9% to $751.9 million, while net income reversed into a substantial net loss of $197.8 million, primarily due to a massive increase in real estate impairment charges from $5.7 million to $323.9 million. Interest expenses also rose by 25.9% to $54.9 million, further pressuring profitability. Total assets saw a slight decrease to $37.38 billion from $37.53 billion, while total liabilities increased by 7.4% to $16.26 billion.

Key Financial Figures

• $0.01 — nge on which registered Common Stock, $0.01 par value per share ARE New York St

Filing Documents

• are-20250930.htm (10-Q) — 9857KB
• a2025-exhibit101.htm (EX-10.1) — 757KB
• a2025-ex221.htm (EX-22.1) — 4KB
• a2025-ex311.htm (EX-31.1) — 11KB
• a2025-ex312.htm (EX-31.2) — 11KB
• a2025-ex313.htm (EX-31.3) — 11KB
• a2025-ex320.htm (EX-32.0) — 10KB
• are-20250930_g1.gif (GRAPHIC) — 20KB
• are-20250930_g10.gif (GRAPHIC) — 41KB
• are-20250930_g11.jpg (GRAPHIC) — 113KB
• are-20250930_g12.jpg (GRAPHIC) — 295KB
• are-20250930_g13.jpg (GRAPHIC) — 782KB
• are-20250930_g14.jpg (GRAPHIC) — 1150KB
• are-20250930_g15.jpg (GRAPHIC) — 1437KB
• are-20250930_g16.jpg (GRAPHIC) — 699KB
• are-20250930_g17.jpg (GRAPHIC) — 353KB
• are-20250930_g18.jpg (GRAPHIC) — 696KB
• are-20250930_g19.jpg (GRAPHIC) — 218KB
• are-20250930_g2.gif (GRAPHIC) — 16KB
• are-20250930_g20.jpg (GRAPHIC) — 396KB
• are-20250930_g21.jpg (GRAPHIC) — 307KB
• are-20250930_g22.jpg (GRAPHIC) — 553KB
• are-20250930_g23.jpg (GRAPHIC) — 568KB
• are-20250930_g24.jpg (GRAPHIC) — 236KB
• are-20250930_g25.jpg (GRAPHIC) — 1393KB
• are-20250930_g26.jpg (GRAPHIC) — 493KB
• are-20250930_g27.jpg (GRAPHIC) — 141KB
• are-20250930_g28.jpg (GRAPHIC) — 148KB
• are-20250930_g29.gif (GRAPHIC) — 35KB
• are-20250930_g3.gif (GRAPHIC) — 12KB
• are-20250930_g30.gif (GRAPHIC) — 35KB
• are-20250930_g31.jpg (GRAPHIC) — 260KB
• are-20250930_g4.gif (GRAPHIC) — 11KB
• are-20250930_g5.gif (GRAPHIC) — 12KB
• are-20250930_g6.gif (GRAPHIC) — 3KB
• are-20250930_g7.gif (GRAPHIC) — 19KB
• are-20250930_g8.gif (GRAPHIC) — 17KB
• are-20250930_g9.gif (GRAPHIC) — 78KB
• 0001035443-25-000198.txt ( ) — 56036KB
• are-20250930.xsd (EX-101.SCH) — 81KB
• are-20250930_cal.xml (EX-101.CAL) — 97KB
• are-20250930_def.xml (EX-101.DEF) — 436KB
• are-20250930_lab.xml (EX-101.LAB) — 938KB
• are-20250930_pre.xml (EX-101.PRE) — 676KB
• are-20250930_htm.xml (XML) — 5454KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION Item 1.

FINANCIAL STATEMENTS (UNAUDITED)

FINANCIAL STATEMENTS (UNAUDITED) Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 .................................................. 1 Consolidated Financial Statements for the Three and Nine Months Ended September 30, 2025 and 2024 : Consolidated Statements of Operations ................................................................................................................... 2 Consolidated Statements of Comprehensive Income ............................................................................................ 3 Consolidated Statements of Changes in Stockholders' Equity and Noncontrolling Interests .......................... 4 Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 ................... 8 Notes to Consolidated Financial Statements .................................................................................................................... 10 Item 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS ........................................................................................................................................................................ 50 Item 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK ......................................................... 129 Item 4. CONTROLS AND PROCEDURES ..................................................................................................................................... 130

– OTHER INFORMATION

PART II – OTHER INFORMATION Item 1. LEGAL PROCEEDINGS ...................................................................................................................................................... 131 Item 1A. RISK FACTORS .................................................................................................................................................................... 132 Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS ................................................... 138 Item 5. OTHER INFORMATION ....................................................................................................................................................... 138 Item 6. EXHIBITS ............................................................................................................................................................................... 139 SIGNATURES ................................................................................................................................................................................................. 140 ii GLOSSARY The following abbreviations or acronyms that may be used in this document shall have the adjacent meanings set forth below: ASU Accounting Standards Update ATM At the Market CAD Canadian Dollar CIP Construction in Progress EPS Earnings per Share FASB Financial Accounting Standards Board FFO Funds From Operations GAAP U.S. Generally Accepted Accounting Principles IRS Internal Revenue Service JV Joint Venture Nareit National Association of Real Estate Investment Trusts NAV Net Asset Value NYSE New York Stock Exchange REIT Real Estate Investment Trust RSF Rentable Square Feet/Foot SEC Securities and Exchange Commission SF Square Feet/Foot SoDo South of Downtown submarket of Seattle SOFR Secured Overnight Financing Rate SoMa South of Market submarket

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

FINANCIAL STATEMENTS (UNAUDITED)

ITEM 1. FINANCIAL STATEMENTS (UNAUDITED) Alexandria Real Estate Equities, Inc. Consolidated Balance Sheets (In thousands) September 30, 2025 December 31, 2024 (Unaudited) Assets Investments in real estate $ 31,743,917 $ 32,110,039 Investments in unconsolidated real estate joint ventures 39,601 39,873 Cash and cash equivalents 579,474 552,146 Restricted cash 4,705 7,701 Tenant receivables 6,409 6,409 Deferred rent 1,257,378 1,187,031 Deferred leasing costs 505,241 485,959 Investments 1,537,638 1,476,985 Other assets 1,700,785 1,661,306 Total assets $ 37,375,148 $ 37,527,449 Liabilities, Noncontrolling Interests, and Equity Secured notes payable $ — $ 149,909 Unsecured senior notes payable 12,044,999 12,094,465 Unsecured senior line of credit and commercial paper 1,548,542 — Accounts payable, accrued expenses, and other liabilities 2,432,726 2,654,351 Dividends payable 230,603 230,263 Total liabilities 16,256,870 15,128,988 Commitments and contingencies Redeemable noncontrolling interests 58,662 19,972 Alexandria Real Estate Equities, Inc.'s stockholders' equity: Common stock 1,703 1,722 Additional paid-in capital 16,669,802 17,933,572 Accumulated other comprehensive loss ( 32,203 ) ( 46,252 ) Alexandria Real Estate Equities, Inc.'s stockholders' equity 16,639,302 17,889,042 Noncontrolling interests 4,420,314 4,489,447 Total equity 21,059,616 22,378,489 Total liabilities, noncontrolling interests, and equity $ 37,375,148 $ 37,527,449 The accompanying notes are an integral part of these consolidated financial statements. 2 Alexandria Real Estate Equities, Inc. Consolidated Statements of Operations (In thousands, except per share amounts) (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Revenues: Income from rentals $ 735,849 $ 775,7

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements (Unaudited) 1. ORGANIZATION AND BASIS OF PRESENTATION Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500 life science REIT, is the pioneer of the life science real estate niche since its founding in 1994. Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative Megacampus ecosystems in AAA life science innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City. As of September 30, 2025 , Alexandria has a total market capitalization o f $ 27.8 billion and an asset base in North America that includes 39.1 million RSF of operating properties and 4.2 million RSF of Class A/A+ properties undergoing construction and one 100% pre-leased committed near-term project expected to commence construction in the next year . As used in this quarterly report on Form 10-Q, references to the "Company," "Alexandria," "ARE," "we," "us," and "our" refer to Alexandria Real Estate Equities, Inc. and its consolidated subsidiaries. The accompanying unaudited consolidated financial statements include the accounts of Alexandria Real Estate Equities, Inc. and its consolidated subsidiaries. All significant intercompany balances and transactions have been eliminated. We have prepared the accompanying interim consolidated financial statements in accordance with GAAP and in conformity with the rules and regulations of the SEC. In our opinion, these interim consolidated financial statements presented herein reflect all adjustments, of a normal recurring nature, that are necessary to fairly present the interim consolidated financial statements. The results of operations for the interim period are not necessarily indicative of the results that may be expected for the year ending December 31, 2025 . These unaudited consolidated financial statements should be read in conjunction with the audited consoli

View Full Filing

View this 10-Q filing on SEC EDGAR